- Home
- ZDAI vs SYBX Comparison
ZDAI vs SYBX Comparison
Compare ZDAI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | SYBX |
|---|---|---|
| Founded | 2022 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 15.2M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZDAI | SYBX |
|---|---|---|
| Price | $0.30 | $1.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 102.2K | 68.3K |
| Earning Date | 12-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,275,673.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.16 | N/A |
| 52 Week Low | $0.29 | $0.90 |
| 52 Week High | $1.85 | $1.96 |
Technical Indicators
Market Signals| Indicator | ZDAI | SYBX |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 26.78 |
| Support Level | $0.33 | $1.01 |
| Resistance Level | $0.37 | $1.20 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 6.07 | 13.89 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.